Lexaria Bioscience Targets Breakthrough in Oral Diabetes Medication

The latest announcement is out from Lexaria Bioscience ( (LEXX) ).

Lexaria Bioscience has announced its strategic decision to explore the commercialization of an orally-dosed version of liraglutide using its DehydraTECH technology, following the drug’s patent expiration. Successful animal studies have shown DehydraTECH-liraglutide’s superior performance in blood sugar and body weight control compared to existing treatments, positioning Lexaria to potentially enter the lucrative GLP-1 weight loss and diabetes market. The company is preparing for pilot clinical trials of this oral formulation, aiming to expand its presence in a market projected to grow significantly.

More about Lexaria Bioscience

Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, focusing on enhancing the administration of pharmaceutical substances. The company’s primary product, DehydraTECH, is a technology designed to improve the delivery and effectiveness of drugs, with a particular focus on pharmaceuticals for weight loss and diabetes management.

YTD Price Performance: -30.87%

Average Trading Volume: 183,479

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $26.5M

Learn more about LEXX stock on TipRanks’ Stock Analysis page.